Group Leader in the Department of Neural Plasticity at the Cajal Institute, Spain
Not Clearly Pro or Con to the question "Should Marijuana Be a Medical Option?"
"We got recently interested on the therapeutic effects of cannabinoids. In collaboration with the group of Prof. M. Guzmán we have found that selective activation of the CB2 receptor, which does not exist in normal brain and does not mediate psycoactive effects [sic], inhibits the growth of gliomas, one of the most malignant brain tumours...
Furthermore, we have demonstrated that both in vitro and in vivo cannabinoids show an 'astroprotective' role, that may result in neuroprotective effects as well."
Experts Individuals with MDs, PhDs, JDs, or equivalent advanced degrees in fields relevant to medical marijuana. Also top-level government officials (such as foreign leaders, US presidents, Founding Fathers, Supreme Court Justices, members of legislative bodies, cabinet members, military leaders, etc.) with positions relevant to medical marijuana issues.
Involvement and Affiliations:
Researcher and Group Leader, Neurochemical Alterations in Neurodegenerative Diseases, Department of Neural Plasticity, Cajal Institute, Spain
Editorial Board, Journal of Neuropathology and Experimental Neurology
Cowritten with I. Lastres-Becker, M. Ceberira, B.-Y. Zeng, P. Jenner, J.A. Ramos and J.J. Fernández-Ruiz, "Increased Cannabinoid CB1 Receptor Binding and Activation of GTP-binding Proteins in the Basal Ganglia of Patients With Parkinson's Syndrome and of MPTP-Treated Marrmosets," European Journal of Neuroscience, 2001
Cowritten with C. Sánchez, T. Gómez del Pulgar, D. Rueda, C. Corbacho, G. Velasco, I. Galve-Roperh, J.W. Huffman, S. Ramón y Cajal and M. Guzmán, "Regression of Gliomas In Vivo By Selective Activation of the CB2 Cannabinoid Receptor," Cancer Research, 2001